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Abstract
Background: This study investigated whether soluble intercellular adhesion molecule-1 (sICAM-1) has a role in the
pathogenesis of macular edema associated with branch retinal vein occlusion (BRVO) together with vascular
endothelial growth factor (VEGF).
Methods: A retrospective case control study was performed in 22 patients with BRVO and macular edema, as well
as 10 patients with nonischemic ocular diseases as the control group. Retinal ischemia was evaluated by measuring
the area of capillary non-perfusion with Scion Image software, while the severity of macular edema was examined
by optical coherence tomography. Aqueous humor samples were obtained during the performance of combined
vitrectomy and cataract surgery. sICAM-1 and VEGF levels in aqueous humor and plasma specimens were
determined by enzyme-linked immunosorbent assay.
Results: Aqueous humor levels of sICAM-1 (median: 6.90 ng/ml) and VEGF (median: 169 pg/ml) were significantly
elevated in BRVO patients compared with the control group (median: 3.30 pg/ml and 15.6 pg/ml, respectively) (P =
0.005 and P < 0.001, respectively). The aqueous humor level of sICAM-1 was significantly correlated with that of
VEGF (P = 0.025). In addition, aqueous levels of both sICAM-1 and VEGF were correlated with the size of the non-
perfused area of the retina in BRVO patients (P = 0.021 and P < 0.001, respectively). Furthermore, aqueous levels of
sICAM-1 and VEGF were both correlated with the severity of macular edema (P = 0.020 and P = 0.005, respectively).
Conclusions: Both sICAM-1 and VEGF may be involved in the pathogenesis of macular edema associated with
BRVO. Measurement of aqueous humor sICAM-1 levels may be useful for assessment of BRVO patients with
macular edema, in addition to measurement of VEGF.
Background
Branch retinal vein occlusion (BRVO) is a common ret-
inal vascular disease that often results in macular
edema, which is the most frequent cause of visual
impairment in patients with BRVO [1,2]. We previously
reported that vascular endothelial growth factor (VEGF)
plays an important role in macular edema associated
with BRVO and in breakdown of the blood-retinal-bar-
rier (BRB). In BRVO patients with macular edema, levels
of various molecules in the aqueous humor have been
measured in the context of anti-VEGF therapy [3].
Among these molecules, VEGF has been reported to be
the major contributor to macular edema associated with
BRVO [4]. However, the pathogenesis of BRVO is com-
plex, so measurement of VEGF alone may not provide
enough information about the disease process or the
response to treatment, including vitrectomy, anti-VEGF
therapy, and intravitreous injection of triamcinolone
acetonide.
Leukocytes also have a role in increasing vascular per-
meability along with VEGF. Leukocytes accumulate in
the tissues through interactions with vascular endothe-
lial cells that are mediated by intercellular adhesion
molecule-1 (ICAM-1) expressed on the vascular
endothelium [5]. VEGF has been reported to increase
ICAM-1 expression by cultured endothelial cells [6].
Although a significant increase of various inflammatory
molecules (interleukin-6, interleukin-8, inducible
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not observed in the aqueous humor of BRVO patients
compared with control patien t s[ 3 ] ,i ti sp o s s i b l et h a t
these inflammatory molecules could promote adhesion
of leukocytes to the vascular endothelium by regulation
of ICAM-1 [7-9]. Thus, the relation between aqueous
levels of ICAM-1 or VEGF and macular edema asso-
ciated with BRVO remain unclear. Accordingly, we mea-
sured the aqueous levels of soluble ICAM-1 (sICAM-1)
and VEGF in BRVO patients with macular edema to
investigate the influence of these molecules on macular
edema in the setting of BRVO.
Methods
Subjects
Undiluted aqueous humor samples were harvested at
the start of combined vitrectomy and cataract surgery
after informed consent was obtained from each subject
following an explanation of the purpose and potential
adverse effects of the procedure. This study was per-
formed in accordance with the Helsinki Declaration of
1975 (1983 revision) and the institutional review board
also approved the protocol for collection of aqueous
humor and blood samples. Consecutive patients with
BRVO presenting to the Department of Ophthalmol-
ogy at Tokyo Women’s Medical University between
November 2006 and June 2009, were screened accord-
ing to the following inclusion and exclusion criteria.
The inclusion criteria were: (1) clinically detectable dif-
fuse macular edema or cystoid macular edema (CME),
(2) best-corrected visual acuity worse than 20/40 in
patients scheduled for combined vitrectomy and catar-
act surgery, and (3) prolonged macular edema even
after photocoagulation. Significant macular edema was
defined as retinal thickening of one optic disc area or
greater in size that involved the fovea [10]. Exclusion
criteria were: (1) previous ocular surgery or intravitr-
eous injection of anti-VEGF agents and triamcinolone
acetonide, (2) diabetes mellitus and diabetic retinopa-
thy, (3) iris rubeosis, and (4) a history of ocular inflam-
mation or vitreoretinal disease. Twenty-two BRVO
patients and 10 patients with nonischemic ocular dis-
eases (control group) were enrolled (Table 1). The 10
control patients included 3 with a macular hole and 7
with an epiretinal membrane; none of them had asso-
ciated proliferative vitreoretinopathy. The BRVO
patients comprised 11 men and 11 women aged 69.3 ±
8.1 years (mean ± SD), while the control group
i n c l u d e d2m e na n d8w o m e na g e d6 8 . 1±6 . 9y e a r s
(Table 1). The mean duration of BRVO was 5.0 ± 2.3
months (range: 3 - 12 months). Preoperative photocoa-
gulation was performed in 4 eyes (mean: 243 shots;
range: 134 to 403), being done within 3.5 ± 1.0 months
(range: 3 to 5 months) before surgery.
Fundus findings
Patients were evaluated by careful biomicroscopic exam-
ination using a fundus contact lens. Fundus findings
were confirmed preoperatively by standardized fundus
color photography. Fluorescein angiography was per-
formed with a Topcon TRC-50EX fundus camera, an
image-net system (Tokyo Optical Co Ltd., Japan), and a
preset lens with a slit-lamp.
Both preoperative and operative fundus findings were
recorded for each subject. A masked grader indepen-
dently assessed ischemic retinal vascular occlusion by
examining the fluorescein angiograms. The ischemic
region of the retina was measured with the public
domain Scion Image program, as reported previously
[11-13]. On digital fundus photographs, the disc area
was outlined with a cursor and then measured, and the
same was done for the non-perfused area. Any sites of
retinal photocoagulation were excluded when calculating
the size of the non-perfused area. The severity of retinal
ischemia was assessed as the non-perfused area divided
by the disc area.
Optical coherence tomography (OCT) was performed
in each subject within 1 week before vitrectomy,
employing an instrument from Zeiss-Humphrey
Ophthalmic Systems (Dublin, California, USA). The fun-
dus was scanned with the measuring beam focused on
horizontal and vertical planes crossing the center of the
fovea, which was located by examination of the fundus
photograph and by each patient’sf i x a t i o n .A l lo ft h e
subjects were able to fix on the central landmark during
the examination. Cross-sectional images were collected
by a single experienced examiner, who continued each
examination until highly reproducible scans were
obtained. The thickness of the central fovea was defined
as the distance between the inner limiting membrane
and the retinal pigment epithelium (including any ser-
ous retinal detachment), and was automatically mea-
sured by computer software. The thickness of the
Table 1 Profile of the BRVO and control groups
BRVO Control P value
P value No.
† (N = 22) No.
† (N = 10)
Gender
Female 11 (50.0%) 8 (80.0%) 0.109
Male 11 (50.0%) 2 (20.0%)
Age (yr) 69.3 ± 8.1
‡ 68.1 ± 6.9
‡ 0.688
Hypertension
No 8 (36.4%) 9 (90.0%) 0.005
Yes 14 (63.6%) 1 (10.0%)
Duration of BRVO (months) 5.0 ± 2.3
‡
†Number of patients with data.
‡Mean ± standard deviation (SD).
NS = not significant.
BRVO = branch retinal vein occlusion.
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Page 2 of 7neurosensory retina was defined as the distance between
the inner and outer neurosensory retinal surfaces [14],
and the severity of macular edema was graded from the
measured retinal thickness. In the BRVO patients, the
average preoperative retinal thickness was 596 ± 182
μm, with a range of 302 to 975 μm.
Sample collection
Combined vitrectomy and cataract surgery were per-
formed at the Department of Ophthalmology at Tokyo
Women’s Medical University (Chiba, Japan).
Samples of undiluted aqueous humor (100-200 μl)
were collected into sterile tubes at the start of surgery
and were rapidly frozen at -80°.
Blood samples were simultaneously collected and cen-
trifuged at 3,000 g for 5 minutes to obtain plasma,
which was aliquoted and stored at -80° until assay.
Measurement of sICAM-1 and VEGF
Levels of sICAM-1 and VEGF were measured in aqueous
humor and plasma with enzyme-linked immunosorbent
assay kits for human VEGF and sICAM-1 (R&D Systems,
Minneapolis, MN, USA) [15]. The VEGF kit detected two
of the four VEGF isoforms (VEGF121 and VEGF165). The
levels of these factors in the aqueous humor and plasma
were within the detection ranges of both assays, with the
minimum detectable concentration being 15.6 pg/ml for
VEGF (intra-assay coefficient of variation (CV): 5.5%;
inter-assay CV: 6.9%) and 3.3 ng/ml for sICAM-1 (intra-
assay CV: 5.4%; inter-assay CV: 7.7%).
Statistical analysis
All analyses were performed with SAS System 9.1 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).
Data are presented as the mean ± SD or as the median
with interquartile range or frequency. Student’s t-test
was employed to compare normally distributed unpaired
continuous variables between the two groups and the
Mann-Whitney U test was used for other variables with
a normal distribution. The paired t-test or Wilcoxon’s
signed-rank test was employed to compare paired con-
tinuous variables. To examine the relations between
sICAM-1 or VEGF and the severity of BRVO, Spear-
man’s rank-order correlation coefficients were calculated
and multiple linear regression analysis was also
employed. Two-tailed P values of less than 0.05 were
considered to indicate statistical significance.
Results
Aqueous humor levels of sICAM-1 and VEGF
Aqueous levels of sICAM-1 (median [range]) were sig-
nificantly elevated in the BRVO patients (6.90 pg/ml
[3.60-7.70]) compared with the control subjects (3.30
pg/ml [3.30-6.70]; P = 0.005; Figure 1A). Aqueous levels
of VEGF were also significantly higher in the patients
with BRVO (169 pg/ml [78.2-244]) than in the controls
(15.6 pg/ml [15.6-15.6]; P < 0.001; Figure 1B). In addi-
tion, aqueous levels of sICAM-1 and VEGF were signifi-
cantly correlated in the BRVO patients (Ρ =0 . 4 9 ,
P = 0.025; Figure 2).
Influence of sICAM-1 and VEGF on ischemia and macular
edema in BRVO
In the BRVO patients, aqueous humor levels of both
sICAM-1 and VEGF were significantly correlated with
the nonperfused area of the retina (sICAM-1, r = 0.51,
P = 0.021; VEGF, r =0 . 7 7 ,P < 0.001; Figure 3A and
3B). In addition, aqueous levels of both sICAM-1 and
Figure 1 (A) Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in the aqueous humor of non-ischemic control
patients and branch retinal vein occlusion (BRVO) patients with macular edema (*P = 0.005); (B) Vascular endothelial growth factor
(VEGF) concentrations in the aqueous humor of non-ischemic control patients and BRVO patients with macular edema (*P < 0.001).
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thickness at the central fovea (sICAM-1, r =0 . 5 1 ,P =
0.020; VEGF, r = 0.61, P = 0.005; Figure 4A and 4B).
There was no significant difference of sICAM-1 or
VEGF levels between the 4 patients (4 eyes) who
received preoperative retinal photocoagulation and the
18 patients (18 eyes) without retinal photocoagulation
(data not shown, P = 0.349 and P = 0.217, respectively).
The aqueous level of sICAM-1 was not significantly cor-
related with either the extent or the timing of retinal
photocoagulation in the 4 treated patients (r = 0.20, P =
0.729 and r =0 . 6 5 ,P = 0.348, respectively). The aqu-
eous VEGF level also showed no significant correlation
with the extent or timing of photocoagulation (r = 0.40,
P = 0.488 and r = 0.63, P = 0.365, respectively).
Aqueous and plasma levels of sICAM-1 and VEGF
In BRVO patients, the aqueous level of VEGF was sig-
nificantly higher than its plasma level (15.6 pg/ml [15.6-
42.1]) (P < 0.001), while the aqueous level of sICAM-1
was significantly lower than its plasma level (381 pg/ml
[316-423]) (P < 0.001). No correlations were observed
between the aqueous and plasma concentrations of
these molecules (sICAM-1, r = -0.04, P = 0.837; VEGF,
Figure 2 Relation between the aqueous humor levels of
soluble intercellular adhesion molecule-1 (sICAM-1) and
vascular endothelial growth factor (VEGF) and in patients with
macular edema and branch retinal vein occlusion (BRVO)
(r = 0.49, P = 0.025).
Figure 3 Correlation between the severity of retinal ischemia and the aqueous humor levels of sICAM-1 and VEGF. Retinal ischemia was
evaluated by measuring the non-perfused area using Scion Image. The aqueous humor levels of sICAM-1 and VEGF were significantly correlated
with the nonperfused area of the retina (sICAM-1, r = 0.51, P = 0.021; VEGF, r = 0.77, P < 0.001)
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relations between the aqueous level of sICAM-1 and the
a g eo ft h es u b j e c t s ,p r e s e n c eo fh y p e r t e n s i o n ,o rd u r a -
tion of BRVO (data not shown, p = 0.166, p = 0.865,
and p = 0.216, respectively). Furthermore, there were no
significant correlations between the aqueous level of
VEGF and these variables (data not shown, p = 0.548,
p = 0.785, and p = 0.606, respectively).
Discussion
The major findings of this s t u d yw e r ea sf o l l o w s :( 1 )
aqueous humor levels of VEGF and sICAM-1 were sig-
nificantly higher in BRVO patients with macular edema
than in control patients, (2) the aqueous levels of both
VEGF and sICAM-1 were significantly correlated with
the nonperfused area of the retina in BRVO patients, (3)
aqueous levels of both VEGF and sICAM-1 were signifi-
cantly correlated with the retinal thickness at the central
fovea in BRVO patients, and (4) aqueous levels of VEGF
and sICAM-1 showed a significant positive correlation
with each other. These findings suggest that both VEGF
and sICAM-1 may play an important role in macular
edema associated with BRVO and breakdown of the
BRB.
In this study, we demonstrated that the aqueous level
of sICAM-1 was significantly correlated with the non-
perfused area of the retina. This finding is supported by
previous reports that the expression of ICAM-1 mRNA
and protein is increased by retinal ischemia [16,17].
Therefore, changes of the intraocular ICAM-1 may
influence the development of macular edema associated
with BRVO. Increased ICAM-1 expression, leads to an
increase of the rolling and adhesion of leukocytes to
vein wall. After retinal vein occlusion, leukocytes are
reported to show an increase of rolling and adhesion
that leads to stagnation of flow [18]. Leukocytes also
release substances that can damage endothelial cells and
thus increase leakage from the retinal microvessels. In
this context, it was reported that moderately elevated
ICAM-1 expression reduces endothelial cell barrier
function and that higher ICAM-1 expression affects cell
junctions [19]. Macular ischemia associated with BRVO
and chronic trapping of leukocytes in the retinal capil-
laries may promote the increased production of factors
like VEGF that increase vascular permeability [6], thus
leading to the development/progression of macular
edema.
We also found that the aqueous level of sICAM-1 was
significantly correlated with the retinal thickness at the
central fovea, and that aqueous levels of sICAM-1 were
significantly correlated with those of VEGF. It has been
reported that VEGF increases the production of ICAM-
1 by capillary endothelial cells in a dose-dependent and
time-dependent manner, and that intravitreal injection
Figure 4 Correlation between the severity of macular edema and the aqueous levels of sICAM-1 and VEGF. The severity of macular
edema was evaluated by optical coherence tomography. Aqueous humor levels of sICAM-1 and VEGF were significantly correlated with the
retinal thickness at the central fovea (sICAM-1, r = 0.51, P = 0.020; VEGF, r = 0.61, P = 0.005).
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increases ICAM-1 protein and mRNA levels in the ret-
inal vasculature [6]. It has been suggested that VEGF-
induced breakdown of the BRB is partly dependent on
leukocytes, because inhibition of ICAM-1 expression
prevents the breakdown of this barrier in the eyes of
rats treated with VEGF [20]. Blocking of sICAM-1 with
a neutralizing antibody was also reported to suppress
both retinal leukostasis and breakdown of the BRB [20].
Thus, VEGF increases ICAM-1 expression by capillary
endothelial cells in vitro and by the retinal vasculature
in vivo, so that an increase of VEGF production may be
responsible for increasing retinal ICAM-1 expression
that mediates adhesion of leukocytes to the retinal ves-
sels of BRVO patients. On the other hand, although var-
ious inflammatory molecules (IL-6, IL-8, IP-10, and
MCP-1) have been suggested to promote leukocyte
adhesion to the vascular endothelium via regulation of
ICAM-1 [7-9], significantly increased concentrations of
these inflammatory molecules have not been found in
aqueous humor samples of BRVO patients compared
with control patients [3], and the aqueous level of IL-6
is not significantly correlated with the retinal thickness
at the central fovea [11]. Taken together, the results of
this study and such findings suggest that measurement
of sICAM-1 (and VEGF) in the aqueous humor may be
more useful than these other inflammatory molecules
for monitoring BRVO patients with macular edema.
H o w e v e r ,o u rs a m p l es i z ew a ss m a l l ,s oal a r g e rp r o -
spective investigation will be required to confirm the
influence of these molecules on macular edema asso-
ciated with BRVO.
Recently, in the Standard Care vs Corticosteroid for
Retinal Vein Occlusion (SCORE) study [21], intravitreal
injection of triamcinolone acetonide was reported to
improve visual acuity and macular edema after 12
months in patients with BRVO, although there was no
difference of visual acuity between the standard care
group (grid photocoagulation) and the triamcinolone
group. Injection of triamcinolone acetonide may reduce
production of ICAM-1 [22-24], thus decreasing leuko-
cyte adhesion and avoiding breakdown of the BRB and
increased vascular permeability [5,20]. Our results taken
together with such reports suggest that sICAM-1 could
be a potential target for preventing an increase of vascu-
lar permeability in BRVO patients with macular edema.
Thus, measuring aqueous sICAM-1 levels may help to
select the treatment strategy for BRVO-associated macu-
lar edema. If the aqueous level of sICAM-1 is high,
patients should be considered for both anti-VEGF ther-
apy and intravitreal injection of triamcinolone acetonide.
The present study demonstrated that there was no sig-
nificant difference of aqueous sICAM-1 and VEGF levels
between 4 eyes that received preoperative laser
photocoagulation and 18 eyes without retinal photocoa-
gulation. In addition, aqueous levels of sICAM-1 and
VEGF showed no significant correlation with the extent
or timing of retinal photocoagulation in the 4 eyes that
received preoperative treatment. Musashi et al. [25]
reported that the number of leukocytes showing behavior
such as rolling and infiltration was increased from 12
hours after laser photocoagulation, but returned to base-
line by 48 hours, and that retinal ICAM-1 mRNA expres-
sion was also upregulated in pigmented male rats after
laser photocoagulation. These findings suggest that upre-
gulation of ICAM-1 mRNA may occur transiently from
about 12 to 48 hours after photocoagulation. Laser
photocoagulation has also been reported to increase the
expression of VEGF and transcription factors by cultured
human retinal pigment epithelial (RPE) cells, with upre-
gulation of VEGF from 6 hours to 72 hours [26]. In con-
trast, Itaya et al. [27] reported that the maximum VEGF
level was detected on day 3 in vivo, coinciding with the
peak of macrophage infiltration. Furthermore, changes of
retinal VEGF mRNA expression in miniature pigs after
laser photocoagulation were confined to RPE cells, with
reduced expression immediately after photocoagulation
and normalization by 42 days [28]. Together with our
results, these reports suggest that retinal ICAM-1 and/or
VEGF expression only shows a transient increase after
photocoagulation, and that ICAM-1/VEGF levels return
to baseline relatively rapidly. Because the average interval
from laser photocoagulation to vitrectomy was 3.5
months in our study, laser therapy is unlikely to have
influenced the levels of sICAM-1 and/or VEGF. How-
ever, further investigation will be needed to clarify the
relations between the extent and timing of photocoagula-
tion and aqueous levels of sICAM-1 and/or VEGF.
Conclusions
In conclusion, we found that the aqueous humor level of
sICAM-1 was significantly correlated with the retinal
thickness at the central fovea, and that it was also signif-
icantly correlated with the aqueous humor level of
VEGF. These results suggest that measurement of aqu-
eous sICAM-1 levels may also be useful for monitoring
BRVO patients with macular edema, in addition to mea-
surement of VEGF.
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